Transduction pathways for growth stimulatory and inhibitory actions of vasoactive agents.
Newby
A C
AC
Department of Cardiology, University of Wales College of Medicine, Cardiff, UK.
Assender
J W
JW
Evans
M A
MA
Lim
K
K
Bennett
M R
MR
Evan
G I
GI
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D001013:Aorta, Thoracic / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D002118:Calcium / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000502:physiology; D008955:Models, Cardiovascular; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D015240:Phorbol 12,13-Dibutyrate / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011493:Protein Kinase C / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000494:pharmacology*; D015398:Signal Transduction
D010982:Platelet-Derived Growth Factor; D015124:8-Bromo Cyclic Adenosine Monophosphate; D012701:Serotonin; D015240:Phorbol 12,13-Dibutyrate; D000242:Cyclic AMP; D011493:Protein Kinase C; D002118:Calcium; D015056:1-Methyl-3-isobutylxanthine